Navigation Links
Prevention in Medical Technology

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

--Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity Preclinically-- --Broad Potential Applications Include Neuropathies, Alzheimer's and Huntington's Disease and Others-- RESEARCH TRIANGLE PARK, N.C., June 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a...

New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform

WASHINGTON, June 8 /PRNewswire-USNewswire/ -- Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF) released a new public opinion survey today which finds that Americans rank prevention as the most important health care reform priority, and overwhelmingly support increasi...

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans

MONTEREY, Calif., June 2 /PRNewswire/ -- This month's Journal of Aerosol Medicine and Pulmonary Drug Delivery features positive Phase Ib clinical trial results for PARI Pharma's L-CsA, inhaled liposomal cyclosporine A. In May, PARI Pharma received Orphan Drug Designation from the Food and Drug Ad...

Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS

- Phase II clinical trial investigating the effectiveness of Intercell's Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine started today in the U.S. - The study is fully funded by HHS - this is the second study conducted under a 5 year USD 128 m ...

Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

HAYWARD, Calif., March 24 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data from the first cohort of 30 patients, an independent Data S...

Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients

ASHBURN, Va., March 19 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the second of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R)...

Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients

ASHBURN, Va., March 16 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) ...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

Results of NIH-sponsored Clinical Trial to be Presented at Retrovirus Conference LEXINGTON, Mass., Feb. 9 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) announced today that a National Institutes of Health (NIH)-sponsored clinical study found that participating wome...

Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children

COLLEGEVILLE, Pa., Dec. 3 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced today that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for approval to market its investigational 13-valent pneumococcal...

Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts

WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- The following is being released by Center for Health & Gender Equity: WHAT: World AIDS Day Audio Media Conference WHEN: Tuesday, November 25, 2008 11:00 a.m. EST Call-in number: 1-800-949-8476 RSVP strongly ...

Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death

Long-term benefits of preventing heart attacks highlighted in new study presented at global health outcomes meeting ATHENS, Greece, Nov. 9 /PRNewswire-FirstCall/ -- Despite substantial progress in the diagnosis and treatment of heart attack patients, prevention of recurrent heart ...

MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine

GAITHERSBURG, Md., Nov. 3 /PRNewswire/ -- MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most ...

New Studies Highlight Benefits of Coblation(R)-Assisted Procedures in Airway Fire Prevention and Endoscopic Sinus Surgery

Results Presented at the American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting CHICAGO, Sept. 24 /PRNewswire/ -- In studies presented this week at the American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting, researchers found that Coblat...

CMV Disease in Stem Cell Transplantation: Prevention and Drug Resistance

A Complimentary Continuing Education Activity VOORHEES, N.J., Aug. 14 /PRNewswire/ -- Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in recipients of hematopoietic stem cell transplantation. The clinical manifestations of CMV disease are serious and range ...

New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option

Now is the time to anticipate and plan for various study outcomes MEXICO CITY, Aug. 3 /PRNewswire/ -- The AIDS Vaccine Advocacy Coalition (AVAC) today released a new report, Anticipating the Results of PrEP Trials, calling for increased action from governments, global health institutions, d...

HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference

RESEARCH TRIANGLE PARK, N.C., July 27 /PRNewswire/ -- Timothy Mastro, MD, FACP, DTM&H, who joins Family Health International (FHI) on August 1st as Senior Director of Research, will share information on promising research into pre-exposure prophylaxis (PrEP) for HIV prevention at the Internati...

Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer

SEATTLE, July 23 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has filed an Investigational New Drug Application with the FDA for the clinical testing of a proprietary formulation of ebselen for the prevention of chemotherapy induced hearing loss or ototoxicity. The oral capsule containing ebsel...

U.S. Prevention Medicine: Employers Can Help Workers Avoid Heart Attacks

Prevention Expert Offers Tips for Benefits/HR Managers DALLAS, June 23 /PRNewswire/ -- Employers and their corporate human resources departments can play an important role in preventing their workers from suffering crippling or fatal heart attacks, according to a leading prevention ex...

CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck

LOS ANGELES, June 23 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. (OTC: CBIA), is pleased to announce that the South African Medicines Control Council has granted approval for a Phase II study in 30 cancer patients evaluating the protective effect of CB1400 on the gastrointestional tract ...

FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture

- Revised label includes data showing 35% reduction in new clinical fractures in patients treated with Reclast following a recent hip fracture(1) - Few patients currently receive osteoporosis treatment following hip fracture despite high risk of morbidi...

Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections

ASHBURN, Va., April 30 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last of three planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatmen...

Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool

MedMined(TM) services from Cardinal Health Equip Hospitals to Measure Infection Performance Against Peers to Facilitate Best Practice Identification and Sharing DUBLIN, Ohio, April 29 /PRNewswire-FirstCall/ -- Cardinal Health, a global provider of products and service...

DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

SAN MATEO, Calif., April 16 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Boar...

New York Infection Prevention Expert Named Recipient of Carole DeMille Award

WASHINGTON, April 8, 2008 /PRNewswire-USNewswire/ -- The Association for Professionals in Infection Control and Epidemiology (APIC) today announced that Rachel L. Stricof, MT, MPH, of Albany, NY, has been named the 2008 recipient of the prestigious Carole DeMille Achievement Award. APIC...

Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections

ASHBURN, Va., Feb. 19 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the second of two phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the p...

Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of DG051 for the Prevention of Heart Attack

REYKJAVIK, Iceland, Jan. 9 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN ) today announced positive topline results from its Phase IIa clinical trial for DG051, the company's leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack. With these results, t...

DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia

Patent Protects Very Low Dose Glucagon ahead of Phase 2 Clinical Trials in 2008 SAN FRANCISCO, Jan. 8 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company developing treatments for metabolic diseases, announced today that it has secured a critica...

Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients

ASHBURN, Va., Jan. 2 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the first of two phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the pre...

Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

SAN MATEO, Calif., Dec. 18 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development has granted A-001 orphan drug status fo...

Highmark Presents Work on MRSA Prevention at National Health Care Quality Conference

QualityBLUE program works with hospitals to help reduce spread of MRSA PITTSBURGH, Dec. 11 /PRNewswire/ -- At a national forum on quality in health care, Highmark officials presented information on one aspect of their pay-for-performance program designed to deal with Methicillin Resistant Sta...

Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings

Unique Collaborative Meeting Includes Leading Scientists Investigating Pregnancy and Breast Cancer Prevention HOUSTON, Nov. 15 /PRNewswire/ -- Eighteen scientists investigating novel means for primary prevention of breast cancer by studying the natural impact of pregnancy on b...

Honor Society of Nursing Recognizes Researcher of HIV Risk Prevention for Poor and Underserved

INDIANAPOLIS and DEERFIELD, Ill., Nov. 6 /PRNewswire-FirstCall/ -- In recognition of her research and development of strategies to reduce HIV risk-associated sexual behaviors among African-American, South-African and Latino youth and adults, the Honor Society of Nursing, Sigma Theta Tau Intern...

deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack

REYKJAVIK, Iceland, Oct. 9 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN ) today announced that it has begun enrolling patients for its Phase IIa clinical trial for DG051, the company's leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack. In Phase ...

Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza

SUNNYVALE, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the termination of its contract with the Centers for Disease Control and Prevention (CDC) for development of a rapid point-of-care diagnostic to detect influenza viruses A and B, and the H5N1 "Avian In...

Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention

Paper is First in a Series Based on Presentations from Cervical Cancer Prevention Forum Hosted by SGO CHICAGO, Aug. 3 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) has published the first in a series of four papers on a variety of cervical cancer i...

New Aspirin Recommendation Can Help Prevent Heart Attacks & Strokes, Says Partnership for Prevention

WASHINGTON, March 16 /PRNewswire-USNewswire/ -- A new recommendation from the U.S. Preventive Services Task Force (USPSTF) underscores the value of regular aspirin use in preventing heart attacks and strokes among many adults, the head of Partnership for Prevention said today. The USPSTF foun...

Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention

Company's R&D Update Today Unveils Rich Development Pipeline of Compounds Meeting Important Medical Needs KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today revealed top-line results of a long-term Phase III clinical study of its psych...

Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention

Collaboration with CDC to Focus on Testing of Juvaris JVRS-100 as an Adjuvant with existing H5N1 vaccine for dose-sparing and cross protection PLEASANTON, Calif., Jan. 15 /PRNewswire/ -- Juvaris BioTherapeutics, Inc. announced today that The Centers for Disease Control and Prevention and Ju...

Anastrozole Confirmed Superior in Breast Cancer Prevention

SAN ANTONIO, Dec. 14 /PRNewswire/ -- Anastrozole is more effective than tamoxifen at preventing breast cancer recurrence for periods of at least 10 years in women with hormone-responsive cancers. In addition, the increased risk of fractures that has been seen in some patients being treated wit...

Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2007 - Magen BioSciences, Inc., a specialty dermatology company, today announced the publication of a paper in the March 9, 2007 issue of the journal Cell by its co-founder and board member, David E. Fisher, M.D., Ph.D., that identifies two new functions fo...
Other Tags
(Date:4/16/2014)... Boulder, Colorado, USA - Geoscientists from the north-central U.S. ... 24-25 April to discuss new science, expand on existing ... of the region, with a special emphasis on applied ... talk at 7 p.m. on Thursday by Dr. Kirk ... Natural History. , The meeting is hosted by ...
(Date:4/16/2014)... or to conquer the world? Surprisingly, bacteria also ... in Munich have now shown how these organisms ... , The bacterium Bacillus subtilis is ... on agar surfaces by means of flagella. Alternatively, ... the bacteria proliferate most effectively in this stationary ...
(Date:4/15/2014)... UC Irvine neurobiologists have found that genetically modified neural ... brains of mice with the symptoms and pathology of ... journal Stem Cells Research and Therapy , and ... different mouse models. , Alzheimer,s disease, one of ... accumulation of the protein amyloid-beta in the brain in ...
Breaking Biology News(10 mins):Walking with mammoths and exploring mid-continental geology 2Walking with mammoths and exploring mid-continental geology 3Walking with mammoths and exploring mid-continental geology 4Theoretical biophysics: Adventurous bacteria 2UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
Other Contents